First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker
| Autor: | Debashis Sarker, Aneta Suder, Peter Stephens, Steen Knudsen, Elizabeth Ruth Plummer, Nicola Cresti, Sharon McGonigle, Yvette Drew, Barbara Ink, Marie Foegh, Divyanshu Dua |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research Messenger RNA business.industry Poly ADP ribose polymerase First in human Phase i study 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Drug response Cancer research Biomarker (medicine) Medicine In patient business |
| Zdroj: | Journal of Clinical Oncology. 36:2505-2505 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.2505 |
| Popis: | 2505Background: A phase I study was done to establish the safety, MTD and anti-tumour efficacy of the novel PARP 1/2 and Tankyrase 1/2 inhibitor, 2X-121 (E7449). A novel tumor agnostic molecular bi... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|